Chronotherapie: De Timing van Geneesmiddelen voor Chronisch Zieke Patiënten
Natuurlijke Ritmes: Het Geheim van Ons Innerlijke Klok
Figuur 1. Circadiaanse ritmes
In de wereld van de wetenschap worden natuurlijke biologische ritmes bestudeerd, die de cyclische schommelingen in gedrag, fysiologische processen en moleculaire activiteiten in alle levende organismen reguleren. Deze ritmes, die worden ingedeeld op basis van hun duur, spelen een cruciale rol in ons dagelijks leven. Ons lichaam herbergt een complex systeem van biologische klokken die verantwoordelijk zijn voor het genereren en synchroniseren van deze ritmes.
Een van de belangrijkste klokken, de "meesterklok", bevindt zich in de suprachiasmatische nucleus (SCN) in de hersenen en speelt een cruciale rol bij het afstemmen van ons lichaam op het natuurlijke dag-nacht ritme. Naast de SCN reguleren perifere klokken in verschillende organen en weefsels lokale circadiane ritmes en coördineren deze. Als deze ritmes worden verstoord, bijvoorbeeld door gebrek aan regelmatige licht-donkercycli, kunnen slaapstoornissen en andere gezondheidsproblemen ontstaan.
Chronotherapie in de farmacologie onderzoekt hoe het tijdstip van medicijninname van invloed is op de effectiviteit en veiligheid ervan vanwege circadiane ritmes, die de absorptie, distributie, metabolisme en uitscheiding van geneesmiddelen beïnvloeden. Deze variaties gedurende de dag kunnen leiden tot verschillen in de werkzaamheid en veiligheid van medicijnen. Chronotherapie draait om het aanpassen van het tijdstip van medicatie om in lijn te zijn met de biologische ritmes van het lichaam om therapeutische resultaten te optimaliseren en bijwerkingen te minimaliseren.
De thesis richt zich op het onderzoeken van de oorzaken van ziekten die worden gekenmerkt door circadiaanse ritmepatronen, met name hypertensie (hoge bloeddruk) en reumatoïde artritis. Daarnaast beoogt het onderzoek te begrijpen hoe circadiane ritmes de farmacokinetiek en farmacodynamiek van medicijnen beïnvloeden.
Timing is Alles: Chronotherapie bij Hypertensie en Rheumatoïde arthritis
Hypertensie, gekenmerkt door verhoogde bloeddruk in de slagaders, brengt aanzienlijke gezondheidsrisico's met zich mee. Chronotherapie, waarbij de timing van medicatie wordt afgestemd op circadiane bloeddrukpatronen, wordt steeds belangrijker. Traditioneel worden medicijnen tegen hypertensie 's ochtends ingenomen, maar chronotherapie suggereert dat avonddosering kan helpen om de ochtendstijging van de bloeddruk te voorkomen. Speciale medicijnformuleringen zijn ontwikkeld om therapeutische niveaus tijdens de slaap te handhaven.
Chronotherapie heeft aangetoond dat het de proteïnurie vermindert, de nierfunctie verbetert en het cardiovasculaire risico verlaagt. Over het algemeen biedt het gepersonaliseerde behandeling die aansluit bij het circadiane ritme van de patiënt, wat mogelijk de bloeddrukcontrole verbetert en gezondheidsrisico's vermindert.
Figuur 2. Hypertensie en chronotherapie: pathogenese, voordelen en nadelen.
Reumatoïde artritis (RA) is een chronische inflammatoire ziekte die voornamelijk de gewrichten aantast en ernstig ongemak, stijfheid en invaliditeit kan veroorzaken. RA-symptomen hebben een aanzienlijke invloed op de kwaliteit van leven van patiënten. Het immuunsysteem speelt een cruciale rol bij de ontsteking en circadiane ritmes spelen een rol in de ernst van deze symptomen.
Verschillende geneesmiddelbehandelingen zijn beschikbaar voor RA, en het tijdstip van toediening van deze medicijnen is cruciaal. Chronotherapie heeft veelbelovende resultaten laten zien in de behandeling van RA. Zo kunnen glucocorticoïden zoals prednisone, wanneer ze 's nachts worden toegediend, ochtendstijfheid en vermoeidheid beter verlichten. Op dezelfde manier is gebleken dat het timing van NSAID-doses in de avond effectiever is bij de behandeling van ochtendsymptomen van RA.
PK/PD Magie: Het Geheim van Effectieve Medicijntiming
De thesis richt zich ook op farmacokinetische/farmacodynamische (PK/PD) modellering om de effecten van prednisone en prednisolone te begrijpen. De timing en dosering van deze medicijnen moeten worden geoptimaliseerd om overeen te komen met de natuurlijke fluctuaties van cortisol in het lichaam en de ritmes van het immuunsysteem. De resultaten van deze modellering laten zien dat hogere doses prednisone 's ochtends nodig zijn voor effectieve onderdrukking, terwijl dosering 's avonds efficiënter is.
Chronotherapie: Het Klokje Rond voor Betere Gezondheid
In de behandeling van hypertensie biedt avondtoediening van antihypertensieve medicijnen voordelen, waaronder verbeterde bloeddrukcontrole en verminderd cardiovasculair risico. Chronotherapie bij reumatoïde artritis richt zich op de nachtelijke toename van ontstekingsreacties, wat leidt tot verbeterde symptoombeheersing en verminderde vermoeidheid.
Hoewel veelbelovende resultaten zijn behaald, is verder onderzoek nodig om langetermijnresultaten, variabiliteit bij patiënten en de invloed van chronotherapie op klinische eindpunten te beoordelen. Gepersonaliseerde dosering op basis van PK/PD-modellering biedt potentieel voor het optimaliseren van de behandelingsdoeltreffendheid en het minimaliseren van bijwerkingen.
Al met al laat dit onderzoek zien hoe het begrip van circadiane ritmes en de toepassing van chronotherapie kunnen bijdragen aan een effectievere en gepersonaliseerde behandeling van chronisch zieke patiënten.
Bibliografie
[1] D. Choudhary, H. Goykar, K. Rajpoot, and R. K. Tekade, ‘Chapter 7 - Chronopharmacokinetics’, in Biopharmaceutics and Pharmacokinetics Considerations, R. K. Tekade, Ed., in Advances in Pharmaceutical Product Development and Research, vol. 1. Academic Press, 2021, pp. 163–194. doi: 10.1016/B978-0-12-814425-1.00008-5.
[2] M. H. Smolensky, R. C. Hermida, and Y.-J. Geng, ‘Chronotherapy of cardiac and vascular disease: timing medications to circadian rhythms to optimize treatment effects and outcomes’, Curr. Opin. Pharmacol., vol. 57, pp. 41–48, Apr. 2021, doi: 10.1016/j.coph.2020.10.014.
[3] G. Kaur, C. Phillips, K. Wong, and B. Saini, ‘Timing is important in medication administration: a timely review of chronotherapy research’, Int. J. Clin. Pharm., vol. 35, no. 3, pp. 344–358, Jun. 2013, doi: 10.1007/s11096-013-9749-0.
[4] D. Lu, Z. Wang, and B. Wu, ‘Pharmacokinetics-based Chronotherapy’, Curr. Drug Metab., vol. 23, no. 1, pp. 2–7, 2022, doi: 10.2174/1389200223666220106124218.
[5] D. J. Skene and J. Arendt, ‘Human circadian rhythms: physiological and therapeutic relevance of light and melatonin’, Ann. Clin. Biochem., vol. 43, no. 5, pp. 344–353, Sep. 2006, doi: 10.1258/000456306778520142.
[6] V. S. Ayyar and S. Sukumaran, ‘Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions’, J. Pharmacokinet. Pharmacodyn., vol. 48, no. 3, pp. 321–338, Jun. 2021, doi: 10.1007/s10928-021-09751-2.
[7] B. Lemmer, ‘Relevance for chronopharmacology in practical medicine’, Semin. Perinatol., vol. 24, no. 4, pp. 280–290, Aug. 2000, doi: 10.1053/sper.2000.8595.
[8] D. P. Cardinali, G. M. Brown, and S. R. Pandi-Perumal, ‘Chronotherapy’, Handb. Clin. Neurol., vol. 179, pp. 357–370, 2021, doi: 10.1016/B978-0-12-819975-6.00023-6.
[9] A. B. Webb, N. Angelo, J. E. Huettner, and E. D. Herzog, ‘Intrinsic, nondeterministic circadian rhythm generation in identified mammalian neurons’, Proc. Natl. Acad. Sci. U. S. A., vol. 106, no. 38, pp. 16493–16498, Sep. 2009, doi: 10.1073/pnas.0902768106.
[10] A. Patke, M. W. Young, and S. Axelrod, ‘Molecular mechanisms and physiological importance of circadian rhythms’, Nat. Rev. Mol. Cell Biol., vol. 21, no. 2, Art. no. 2, Feb. 2020, doi: 10.1038/s41580-019-0179-2.
[11] B. Bruguerolle and B. Lemmer, ‘Recent advances in chronopharmacokinetics: methodological problems’, Life Sci., vol. 52, no. 23, pp. 1809–1824, Jan. 1993, doi: 10.1016/0024-3205(93)90001-J.
[12] L. S. Gaspar, A. R. Álvaro, S. Carmo‐Silva, A. F. Mendes, A. Relógio, and C. Cavadas, ‘The importance of determining circadian parameters in pharmacological studies’, Br. J. Pharmacol., vol. 176, no. 16, pp. 2827–2847, Aug. 2019, doi: 10.1111/bph.14712.
[13] U. Schibler and P. Sassone-Corsi, ‘A web of circadian pacemakers’, Cell, vol. 111, no. 7, pp. 919–922, Dec. 2002, doi: 10.1016/s0092-8674(02)01225-4.
[14] E. D. Herzog, T. Hermanstyne, N. J. Smyllie, and M. H. Hastings, ‘Regulating the Suprachiasmatic Nucleus (SCN) Circadian Clockwork: Interplay between Cell-Autonomous and Circuit-Level Mechanisms’, Cold Spring Harb. Perspect. Biol., vol. 9, no. 1, p. a027706, Jan. 2017, doi: 10.1101/cshperspect.a027706.
[15] E. P and B. T, ‘Chronopharmacokinetics of drugs in toxicological aspects: A short review for pharmacy practitioners’, J. Res. Pharm. Pract., vol. 1, no. 1, Jul. 2012, doi: 10.4103/2279-042X.99670.
[16] J. E. Gibbs and D. W. Ray, ‘The role of the circadian clock in rheumatoid arthritis’, Arthritis Res. Ther., vol. 15, no. 1, p. 205, Feb. 2013, doi: 10.1186/ar4146.
[17] R. Dallmann, S. A. Brown, and F. Gachon, ‘Chronopharmacology: New Insights and Therapeutic Implications’, Annu. Rev. Pharmacol. Toxicol., vol. 54, p. 10.1146/annurev-pharmtox-011613–135923, Jan. 2014, doi: 10.1146/annurev-pharmtox-011613-135923.
[18] S. Sukumaran, R. R. Almon, D. C. DuBois, and W. J. Jusko, ‘Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action’, Adv. Drug Deliv. Rev., vol. 62, no. 9, pp. 904–917, Jul. 2010, doi: 10.1016/j.addr.2010.05.009.
[19] A. R. Neves, T. Albuquerque, T. Quintela, and D. Costa, ‘Circadian rhythm and disease: Relationship, new insights, and future perspectives’, J. Cell. Physiol., vol. 237, no. 8, pp. 3239–3256, 2022, doi: 10.1002/jcp.30815.
[20] J. S. Menet, S. Pescatore, and M. Rosbash, ‘CLOCK:BMAL1 is a pioneer-like transcription factor’, Genes Dev., vol. 28, no. 1, pp. 8–13, Jan. 2014, doi: 10.1101/gad.228536.113.
[21] F. Yu, Y. Liu, R. Zhang, L. Zhu, T. Zhang, and Y. Shi, ‘Recent advances in circadian-regulated pharmacokinetics and its implications for chronotherapy’, Biochem. Pharmacol., vol. 203, p. 115185, Sep. 2022, doi: 10.1016/j.bcp.2022.115185.
[22] K. Griffett and T. P. Burris, ‘The mammalian clock and chronopharmacology’, Bioorg. Med. Chem. Lett., vol. 23, no. 7, pp. 1929–1934, Apr. 2013, doi: 10.1016/j.bmcl.2013.02.015.
[23] P. Lewis, H. W. Korf, L. Kuffer, J. V. Groß, and T. C. Erren, ‘Exercise time cues (zeitgebers) for human circadian systems can foster health and improve performance: a systematic review’, BMJ Open Sport Exerc. Med., vol. 4, no. 1, p. e000443, 2018, doi: 10.1136/bmjsem-2018-000443.
[24] S.-H. Yoo et al., ‘PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues’, Proc. Natl. Acad. Sci. U. S. A., vol. 101, no. 15, pp. 5339–5346, Apr. 2004, doi: 10.1073/pnas.0308709101.
[25] H. Reinke, C. Saini, F. Fleury-Olela, C. Dibner, I. J. Benjamin, and U. Schibler, ‘Differential display of DNA-binding proteins reveals heat-shock factor 1 as a circadian transcription factor’, Genes Dev., vol. 22, no. 3, pp. 331–345, Feb. 2008, doi: 10.1101/gad.453808.
[26] C. Vetter, ‘Circadian disruption: What do we actually mean?’, Eur. J. Neurosci., vol. 51, no. 1, pp. 531–550, 2020, doi: 10.1111/ejn.14255.
[27] S. M. Abbott, R. G. Malkani, and P. C. Zee, ‘Circadian disruption and human health: A bidirectional relationship’, Eur. J. Neurosci., vol. 51, no. 1, pp. 567–583, 2020, doi: 10.1111/ejn.14298.
[28] ‘Circadian disruption and human health - PubMed’. https://pubmed.ncbi.nlm.nih.gov/34596053/ (accessed Feb. 22, 2023).
[29] M. L. Phillips, ‘Of owls, larks and alarm clocks: could out-of-sync body clocks be contributing to human disease?’, Nature, vol. 458, no. 7235, pp. 142–145, Mar. 2009.
[30] R. L. Sack, ‘The pathophysiology of jet lag’, Travel Med. Infect. Dis., vol. 7, no. 2, pp. 102–110, Mar. 2009, doi: 10.1016/j.tmaid.2009.01.006.
[31] D. A. Golombek et al., ‘The times they’re a-changing: Effects of circadian desynchronization on physiology and disease’, J. Physiol.-Paris, vol. 107, no. 4, pp. 310–322, Sep. 2013, doi: 10.1016/j.jphysparis.2013.03.007.
[32] K. A. Smith, M. W. Schoen, and C. A. Czeisler, ‘Adaptation of human pineal melatonin suppression by recent photic history’, J. Clin. Endocrinol. Metab., vol. 89, no. 7, pp. 3610–3614, Jul. 2004, doi: 10.1210/jc.2003-032100.
[33] M. R. Smith and C. I. Eastman, ‘Phase delaying the human circadian clock with blue-enriched polychromatic light’, Chronobiol. Int., vol. 26, no. 4, pp. 709–725, May 2009, doi: 10.1080/07420520902927742.
[34] D. P. Cardinali, A. M. Furio, M. P. Reyes, and L. I. Brusco, ‘The Use of Chronobiotics in the Resynchronization of the Sleep–wake Cycle’, Cancer Causes Control, vol. 17, no. 4, pp. 601–609, May 2006, doi: 10.1007/s10552-005-9009-2.
[35] P. Gringras, T. Nir, J. Breddy, A. Frydman-Marom, and R. L. Findling, ‘Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder’, J. Am. Acad. Child Adolesc. Psychiatry, vol. 56, no. 11, pp. 948-957.e4, Nov. 2017, doi: 10.1016/j.jaac.2017.09.414.
[36] T. M. Burke et al., ‘Effects of caffeine on the human circadian clock in vivo and in vitro’, Sci. Transl. Med., vol. 7, no. 305, p. 305ra146, Sep. 2015, doi: 10.1126/scitranslmed.aac5125.
[37] L. Sun et al., ‘Resveratrol restores the circadian rhythmic disorder of lipid metabolism induced by high-fat diet in mice’, Biochem. Biophys. Res. Commun., vol. 458, no. 1, pp. 86–91, Feb. 2015, doi: 10.1016/j.bbrc.2015.01.072.
[38] V. Marks, J. English, W. Aherne, and J. Arendt, ‘Chronopharmacology’, Clin. Biochem., vol. 18, no. 3, pp. 154–157, Jun. 1985, doi: 10.1016/S0009-9120(85)80100-4.
[39] B. Lemmer and G. Labrecque, ‘Chronopharmacology and Chronotherapeutics: Definitions and Concepts’, Chronobiol. Int., vol. 4, no. 3, pp. 319–329, Jan. 1987, doi: 10.3109/07420528709083522.
[40] S. Ohdo, ‘Chronopharmacology Focused on Biological Clock’, Drug Metab. Pharmacokinet., vol. 22, no. 1, pp. 3–14, 2007, doi: 10.2133/dmpk.22.3.
[41] N. P. Bowles, S. S. Thosar, M. X. Herzig, and S. A. Shea, ‘Chronotherapy for Hypertension’, Curr. Hypertens. Rep., vol. 20, no. 11, p. 97, Sep. 2018, doi: 10.1007/s11906-018-0897-4.
[42] J. Cortés-Ríos, R. C. Hermida, and M. Rodriguez-Fernandez, ‘Dosing time optimization of antihypertensive medications by including the circadian rhythm in pharmacokinetic-pharmacodynamic models’, PLoS Comput. Biol., vol. 18, no. 11, p. e1010711, Nov. 2022, doi: 10.1371/journal.pcbi.1010711.
[43] M. Stroh et al., ‘Model-Based Decision Making in Early Clinical Development: Minimizing the Impact of a Blood Pressure Adverse Event’, AAPS J., vol. 11, no. 1, pp. 99–108, Feb. 2009, doi: 10.1208/s12248-009-9083-6.
[44] F. Cao, M. R. Ralph, and A. R. Stinchcombe, ‘A Phenomenological Mouse Circadian Pacemaker Model’, J. Biol. Rhythms, vol. 37, no. 3, pp. 329–342, Jun. 2022, doi: 10.1177/07487304221085455.
[45] D. Gonze and W. Abou-Jaoudé, ‘The Goodwin model: behind the Hill function’, PloS One, vol. 8, no. 8, p. e69573, 2013, doi: 10.1371/journal.pone.0069573.
[46] D. B. Forger, M. E. Jewett, and R. E. Kronauer, ‘A simpler model of the human circadian pacemaker’, J. Biol. Rhythms, vol. 14, no. 6, pp. 532–537, Dec. 1999, doi: 10.1177/074873099129000867.
[47] J. B. Bulitta et al., ‘Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling’, Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci., vol. 107, pp. 32–44, Sep. 2017, doi: 10.1016/j.ejps.2017.06.008.
[48] J. Xu, J. Winkler, S. N. Sabarinath, and H. Derendorf, ‘Assessment of the Impact of Dosing Time on the Pharmacokinetics/Pharmacodynamics of Prednisolone’, AAPS J., vol. 10, no. 2, pp. 331–341, Jun. 2008, doi: 10.1208/s12248-008-9038-3.
[49] I. Prkacin, D. Balenovic, V. Djermanovic-Dobrota, I. Lukac, P. Drazic, and I.-K. Pranjic, ‘Resistant hypertension and chronotherapy’, Mater. Socio-Medica, vol. 27, no. 2, pp. 118–121, Apr. 2015, doi: 10.5455/msm.2015.27.118-121.
[50] P. A. Sarafidis and G. L. Bakris, ‘Resistant Hypertension: An Overview of Evaluation and Treatment’, J. Am. Coll. Cardiol., vol. 52, no. 22, pp. 1749–1757, Nov. 2008, doi: 10.1016/j.jacc.2008.08.036.
[51] J. Park and V. Campese, ‘Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis’, J. Clin. Hypertens. Greenwich Conn, vol. 9, no. 1 Suppl 1, pp. 7–12, Jan. 2007, doi: 10.1111/j.1524-6175.2007.6106.x.
[52] R. C. Hermida, D. E. Ayala, C. Calvo, F. Portaluppi, and M. H. Smolensky, ‘Chronotherapy of hypertension: administration-time-dependent effects of treatment on the circadian pattern of blood pressure’, Adv. Drug Deliv. Rev., vol. 59, no. 9–10, pp. 923–939, Aug. 2007, doi: 10.1016/j.addr.2006.09.021.
[53] C. Thoonkuzhy and M. Rahman, ‘New Insights on Chronotherapy in Hypertension: Is Timing Everything?’, Curr. Hypertens. Rep., vol. 22, no. 4, p. 32, Mar. 2020, doi: 10.1007/s11906-020-1032-x.
[54] R. C. Hermida, R. G. Hermida-Ayala, M. H. Smolensky, A. Mojón, and J. R. Fernández, ‘Ingestion-time differences in the pharmacodynamics of hypertension medications: Systematic review of human chronopharmacology trials’, Adv. Drug Deliv. Rev., vol. 170, pp. 200–213, Mar. 2021, doi: 10.1016/j.addr.2021.01.013.
[55] R. C. Hermida, D. E. Ayala, and F. Portaluppi, ‘Circadian variation of blood pressure: The basis for the chronotherapy of hypertension’, Adv. Drug Deliv. Rev., vol. 59, no. 9, pp. 904–922, Aug. 2007, doi: 10.1016/j.addr.2006.08.003.
[56] P. Gosse, ‘A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours’, Vasc. Health Risk Manag., vol. 2, no. 3, pp. 195–201, 2006, doi: 10.2147/vhrm.2006.2.3.195.
[57] P. Mathur, S. Kadavath, J. D. Marsh, and J. L. Mehta, ‘Chronotherapy for hypertension: improvement in patient outcomes with bedtime administration of antihypertensive drugs’, Eur. Heart J., vol. 41, no. 48, pp. 4577–4579, Dec. 2020, doi: 10.1093/eurheartj/ehz836.
[58] B. Lemmer, ‘Chronopharmacological aspects of PK/PD modelling’, Int. J. Clin. Pharmacol. Ther., vol. 35, no. 10, pp. 458–464, Oct. 1997.
[59] M. G. Ziegler and M. Milic, ‘Sympathetic nerves and hypertension in stress, sleep apnea, and caregiving’, Curr. Opin. Nephrol. Hypertens., vol. 26, no. 1, p. 26, Jan. 2017, doi: 10.1097/MNH.0000000000000288.
[60] R. C. Hermida et al., ‘Chronotherapy improves blood pressure control and reduces vascular risk in CKD’, Nat. Rev. Nephrol., vol. 9, no. 6, Art. no. 6, Jun. 2013, doi: 10.1038/nrneph.2013.79.
[61] ‘A Clinician’s Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy’, 2018.
[62] R. C. Hermida et al., ‘Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial’, Eur. Heart J., vol. 41, no. 48, pp. 4565–4576, Dec. 2020, doi: 10.1093/eurheartj/ehz754.
[63] S. K. Gupta, B. M. Yih, L. Atkinson, and J. Longstreth, ‘The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil’, J. Clin. Pharmacol., vol. 35, no. 11, pp. 1083–1093, Nov. 1995, doi: 10.1002/j.1552-4604.1995.tb04031.x.
[64] M. E. Krecic-Shepard, C. R. Barnas, J. Slimko, and J. B. Schwartz, ‘Faster clearance of sustained release verapamil in men versus women: Continuing observations on sex-specific differences after oral administration of verapamil’, Clin. Pharmacol. Ther., vol. 68, no. 3, pp. 286–292, 2000, doi: 10.1067/mcp.2000.109356.
[65] W. B. White, H. R. Black, M. A. Weber, W. J. Elliott, B. Bryzinski, and T. D. Fakouhi, ‘Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product’, Am. J. Cardiol., vol. 81, no. 4, pp. 424–431, Feb. 1998, doi: 10.1016/s0002-9149(97)00935-1.
[66] S. P. Glasser, ‘Diltiazem hydrochloride: New technologies and evolution of diltiazem’, Clin. Cardiol., vol. 26, no. S4, pp. 16–24, 2003, doi: 10.1002/clc.4960261605.
[67] S. P. Glasser, J. M. Neutel, T. J. Gana, and K. S. Albert, ‘Efficacy and safety of a once daily graded-release diltiazem formulation in essential hypertension’, Am. J. Hypertens., vol. 16, no. 1, pp. 51–58, Jan. 2003, doi: 10.1016/s0895-7061(02)03153-9.
[68] I. Kohno et al., ‘Administration-time-dependent effects of diltiazem on the 24-hour blood pressure profile of essential hypertension patients’, Chronobiol. Int., vol. 14, no. 1, pp. 71–84, Jan. 1997, doi: 10.3109/07420529709040543.
[69] S. Sista, J. C.-K. Lai, O. Eradiri, and K. S. Albert, ‘Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration’, J. Clin. Pharmacol., vol. 43, no. 10, pp. 1149–1157, Oct. 2003, doi: 10.1177/0091270003257214.
[70] Y. Kitahara et al., ‘Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate, and sympathetic nervous activity in essential hypertensive patients’, J. Cardiovasc. Pharmacol., vol. 43, no. 1, pp. 68–73, Jan. 2004, doi: 10.1097/00005344-200401000-00011.
[71] J. A. Staessen et al., ‘Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators’, JAMA, vol. 282, no. 6, pp. 539–546, Aug. 1999, doi: 10.1001/jama.282.6.539.
[72] M. Middeke, M. Klüglich, and H. Holzgreve, ‘Chronopharmacology of captopril plus hydrochlorothiazide in hypertension: morning versus evening dosing’, Chronobiol. Int., vol. 8, no. 6, pp. 506–510, 1991, doi: 10.3109/07420529109059186.
[73] P. Svensson, U. de Faire, P. Sleight, S. Yusuf, and J. Ostergren, ‘Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy’, Hypertens. Dallas Tex 1979, vol. 38, no. 6, pp. E28-32, Dec. 2001, doi: 10.1161/hy1101.099502.
[74] W. B. White, Y. Lacourciere, T. Gana, M. G. Pascual, D. H. Smith, and K. S. Albert, ‘Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product’, Am. Heart J., vol. 148, no. 4, pp. 628–634, Oct. 2004, doi: 10.1016/j.ahj.2004.07.008.
[75] R. C. Hermida, D. E. Ayala, J. R. Fernández, F. Portaluppi, F. Fabbian, and M. H. Smolensky, ‘Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications’, Am. J. Hypertens., vol. 24, no. 4, pp. 383–391, Apr. 2011, doi: 10.1038/ajh.2010.217.
[76] T. G. Pickering, M. Levenstein, and P. Walmsley, ‘Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT Study. Hypertension and Lipid Trial Study Group’, Am. J. Hypertens., vol. 7, no. 9 Pt 1, pp. 844–847, Sep. 1994, doi: 10.1093/ajh/7.9.844.
[77] B. Langner and B. Lemmer, ‘Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects’, Eur. J. Clin. Pharmacol., vol. 33, no. 6, pp. 619–624, 1988, doi: 10.1007/BF00542498.
[78] R. C. Hermida et al., ‘Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects’, Hypertens. Dallas Tex 1979, vol. 42, no. 3, pp. 283–290, Sep. 2003, doi: 10.1161/01.HYP.0000084855.32823.DA.
[79] R. C. Hermida, C. Calvo, D. E. Ayala, and J. E. López, ‘Decrease in Urinary Albumin Excretion Associated With the Normalization of Nocturnal Blood Pressure in Hypertensive Subjects’, Hypertension, vol. 46, no. 4, pp. 960–968, Oct. 2005, doi: 10.1161/01.HYP.0000174616.36290.fa.
[80] H. Rakugi, K. Kario, K. Enya, M. Igeta, and Y. Ikeda, ‘Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension’, Blood Press., vol. 22 Suppl 1, pp. 22–28, Sep. 2013, doi: 10.3109/08037051.2013.818758.
[81] C. Calvo et al., ‘[Chronotherapy with torasemide in hypertensive patients: increased efficacy and therapeutic coverage with bedtime administration]’, Med. Clin. (Barc.), vol. 127, no. 19, pp. 721–729, Nov. 2006, doi: 10.1157/13095521.
[82] R. C. Hermida et al., ‘Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension’, Chronobiol. Int., vol. 25, no. 6, pp. 950–970, Nov. 2008, doi: 10.1080/07420520802544589.
[83] P. M. Ridker, J. E. Manson, J. E. Buring, J. E. Muller, and C. H. Hennekens, ‘Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians’, Circulation, vol. 82, no. 3, pp. 897–902, Sep. 1990, doi: 10.1161/01.cir.82.3.897.
[84] R. C. Hermida et al., ‘Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives’, Hypertens. Dallas Tex 1979, vol. 46, no. 4, pp. 1060–1068, Oct. 2005, doi: 10.1161/01.HYP.0000172623.36098.4e.
[85] ‘Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework’, Lancet Lond. Engl., vol. 351, no. 9098, pp. 233–241, Jan. 1998.
[86] R. Minutolo et al., ‘Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial’, Am. J. Kidney Dis. Off. J. Natl. Kidney Found., vol. 50, no. 6, pp. 908–917, Dec. 2007, doi: 10.1053/j.ajkd.2007.07.020.
[87] M. Krasselt and C. Baerwald, ‘Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis’, Drug Des. Devel. Ther., vol. 10, pp. 1047–1058, 2016, doi: 10.2147/DDDT.S87792.
[88] M. Cutolo, ‘Glucocorticoids and chronotherapy in rheumatoid arthritis’, RMD Open, vol. 2, no. 1, p. e000203, 2016, doi: 10.1136/rmdopen-2015-000203.
[89] S. Paolino, M. Cutolo, and C. Pizzorni, ‘Glucocorticoid management in rheumatoid arthritis: morning or night low dose?’, Reumatologia, vol. 55, no. 4, pp. 189–197, 2017, doi: 10.5114/reum.2017.69779.
[90] R. H. Straub and M. Cutolo, ‘Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management’, Arthritis Rheum., vol. 56, no. 2, pp. 399–408, Feb. 2007, doi: 10.1002/art.22368.
[91] A. Sulli et al., ‘Melatonin serum levels in rheumatoid arthritis’, Ann. N. Y. Acad. Sci., vol. 966, pp. 276–283, Jun. 2002, doi: 10.1111/j.1749-6632.2002.tb04227.x.
[92] H. Ø. Hjortkjær et al., ‘Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping: a randomised, placebo-controlled, double-blind cross-over trial’, BMJ Open, vol. 6, no. 12, p. e012307, Dec. 2016, doi: 10.1136/bmjopen-2016-012307.
[93] R. H. Straub, ‘Concepts of evolutionary medicine and energy regulation contribute to the etiology of systemic chronic inflammatory diseases’, Brain. Behav. Immun., vol. 25, no. 1, pp. 1–5, Jan. 2011, doi: 10.1016/j.bbi.2010.08.002.
[94] S. L. Gorter et al., ‘Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis’, Ann. Rheum. Dis., vol. 69, no. 6, pp. 1010–1014, Jun. 2010, doi: 10.1136/ard.2009.127332.
[95] J. S. Smolen et al., ‘EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update’, Ann. Rheum. Dis., vol. 76, no. 6, pp. 960–977, Jun. 2017, doi: 10.1136/annrheumdis-2016-210715.
[96] M. Cutolo, K. Otsa, O. Aakre, and A. Sulli, ‘Nocturnal hormones and clinical rhythms in rheumatoid arthritis’, Ann. N. Y. Acad. Sci., vol. 1051, pp. 372–381, Jun. 2005, doi: 10.1196/annals.1361.079.
[97] F. Buttgereit, J. S. Smolen, A. N. Coogan, and C. Cajochen, ‘Clocking in: chronobiology in rheumatoid arthritis’, Nat. Rev. Rheumatol., vol. 11, no. 6, pp. 349–356, Jun. 2015, doi: 10.1038/nrrheum.2015.31.
[98] ‘Figure 4 Pharmacokinetics of conventional and modified-release (MR)...’, ResearchGate. https://www.researchgate.net/figure/Pharmacokinetics-of-conventional-an… (accessed May 10, 2023).
[99] H. Derendorf, K. Ruebsamen, L. Clarke, A. Schaeffler, and J. R. Kirwan, ‘Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis’, J. Clin. Pharmacol., vol. 53, no. 3, pp. 326–333, Mar. 2013, doi: 10.1177/0091270012444315.
[100] M. Cutolo, ‘Circadian rhythms and rheumatoid arthritis’, Joint Bone Spine, vol. 86, no. 3, pp. 327–333, May 2019, doi: 10.1016/j.jbspin.2018.09.003.
[101] F. Buttgereit et al., ‘Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial’, Lancet Lond. Engl., vol. 371, no. 9608, pp. 205–214, Jan. 2008, doi: 10.1016/S0140-6736(08)60132-4.
[102] M. Cutolo, L. Iaccarino, A. Doria, M. Govoni, A. Sulli, and C. Marcassa, ‘Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids’, Clin. Exp. Rheumatol., vol. 31, no. 4, pp. 498–505, 2013.
[103] M. Cutolo, A. Sulli, and T. Pincus, ‘Circadian use of glucocorticoids in rheumatoid arthritis’, Neuroimmunomodulation, vol. 22, no. 1–2, pp. 33–39, 2015, doi: 10.1159/000362733.
[104] B. M. Pfeiffer et al., ‘Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis’, Rheumatol. Int., vol. 33, no. 6, pp. 1447–1454, Jun. 2013, doi: 10.1007/s00296-012-2583-1.
[105] R. Alten et al., ‘Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone’, J. Rheumatol., vol. 37, no. 10, pp. 2025–2031, Oct. 2010, doi: 10.3899/jrheum.100051.
[106] G. Kaur, Y.-L. Gan, C. L. Phillips, K. Wong, and B. Saini, ‘Chronotherapy in practice: the perspective of the community pharmacist’, Int. J. Clin. Pharm., vol. 38, no. 1, pp. 171–182, Feb. 2016, doi: 10.1007/s11096-015-0228-7.
